Details for Patent: 8,680,111
✉ Email this page to a colleague
Which drugs does patent 8,680,111 protect, and when does it expire?
Patent 8,680,111 protects LORBRENA and is included in one NDA.
This patent has fifty-nine patent family members in forty-eight countries.
Summary for Patent: 8,680,111
| Title: | Macrocyclic derivatives for the treatment of diseases |
| Abstract: | The invention relates to compounds of formula (.PHI.) ##STR00001## as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer. |
| Inventor(s): | Bailey; Simon (San Diego, CA), Burke; Benjamin Joseph (San Diego, CA), Collins; Michael Raymond (San Diego, CA), Cui; Jingrong Jean (San Diego, CA), Deal; Judith Gail (Wildomar, CA), Hoffman; Robert Louis (San Marcos, CA), Huang; Qinhua (San Diego, CA), Johnson; Ted William (Carlsbad, CA), Kania; Robert Steven (San Diego, CA), Kath; John Charles (La Mesa, CA), Le; Phuong Thi Quy (San Diego, CA), McTigue; Michele Ann (Encinitas, CA), Palmer; Cynthia Louise (La Mesa, CA), Richardson; Paul Francis (San Diego, CA), Sach; Neal William (San Diego, CA) |
| Assignee: | Pfizer Inc. (New York, NY) |
| Application Number: | 13/786,106 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,680,111
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | LORBRENA | lorlatinib | TABLET;ORAL | 210868-001 | Nov 2, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Pfizer | LORBRENA | lorlatinib | TABLET;ORAL | 210868-002 | Nov 2, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,680,111
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 090230 | ⤷ Try a Trial | |||
| Australia | 2013229173 | ⤷ Try a Trial | |||
| Brazil | 112014022106 | ⤷ Try a Trial | |||
| Canada | 2863892 | ⤷ Try a Trial | |||
| Chile | 2014002084 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
